Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “AMITRIPTYLINE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 721 records · Page 40Linked to original sources
PubMedDate not supplied

[The treatment of migraine and tension headaches with amitriptyline (author's transl)].

Study of 100 patients followed up for over one year, including 26 cases of migraine (4 classical migraine) and 74 cases of tension headache associated or not with muscular tension. With dihydroergotamin alone 16 cases of migraine, and with amitriptyline alone 17 cases experienced excellent to fair relief, while with the association of both drugs, 21 excellent results were obtained. Among tension headaches patients, 53 were relieved with amitriptyline alone, 56 when DHE was added. The activity of amitriptyline in lower dosages is very likely not an anti-depressant one, but connected with catecholamines metabolism. Dosage must be adjusted in each individual case. The efficiency of DHE in tension headaches suggest a possible part of vaso-motor mechanisms in such cases.

Adult↗
PubMed1989

Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline.

Thirty-six patients with fibrositis received low dose amitriptyline and placebo in a randomized double blind crossover study lasting 10 weeks. Amitriptyline was associated with significant changes on the outcome measures of pain, tender point sensitivity and patient assessment of well being. Clinically significant improvements for pain and tender point sensitivity and a statistically significant improvement in generalized pain responsiveness were found between patients who reported subjective improvement on amitriptyline and those who felt no change.

Adult↗
PubMedDate not supplied

Interaction between central effects of ethanol and tricyclic antidepressants, imipramine and amitriptyline in mice and rats.

The effect of a combined treatment with ethanol and imipramine or amitriptyline was tested in mice and rats. The antidepressants were given in one or, in some experiments, in 21 daily doses of 10 mg/kg each. In mice the effect of antidepressants was tested on acute toxicity, disturbances of rota-rod performance, hypothermia and sleeping induced by ethanol, in rats the effect of the antidepressants on the development of tolerance to sleep-inducing and hypothermic action of ethanol was investigated. Amitriptyline showed a tendency to pontentiate the ethanol-induced acute toxicity, while imipramine did not change it. Given in a single dose the antidepressants have a tendency to potentiate the impairment of motor coordination induced by ethanol, but after a prolonged administration did not influence the ethanol effect in the rota-rod test. The antidepressants enhance ethanol-induced hypothermia and prolong the ethanol sleeping time. The development of tolerance to hypnotic effect of ethanol in rats is not affected by amitriptyline and imipramine, but the antidepressants prevent the development of tolerance to hypothermic effect.

Amitriptyline↗
PubMedDate not supplied

[Comparative clinico-therapeutic study of amitriptyline hydrochloride (Tryptizol/amitriptyline)].

As compared to the psychopharmacological profile of amitriptyline hydrochloride the authors analyse the findings of a comparative clinical trial amitriptyline versus Tryptizol regarding their efficacy in neurotic and presenile depression. 170 inpatients divided into four comparative series were investigated. The drugs were administered according to the same scheme in monotherapy for 30 days. The efficiency and tolerance of these drugs were estimated through clinical observations, the recording of the first ameliorated state and the maximum one, psychological check-up by using Hamilton's scale for depressions, paraclinical investigation, recording of side effects, clinical and paraclinical screening for 0-10-20-30 days. The analysis of clinical findings in the investigated series reveals for both drugs their easy administration, tolerance, incidence and low intensity of the side effects. The comparative estimation of the treatment with amitriptyline and Tryptizol in neurotic and presenile depressions attests a similar therapeutic efficiency.

Adolescent↗
PubMed1988

Differential effect of amitriptyline and bupropion on primary and secondary depression: a pilot study.

In a prospective, controlled, double-blind study, 37 patients with major depressive disorder were subclassified into primary depression (N = 25) and secondary (N = 12) depression and treated with either amitriptyline (primary depressives N = 13, secondary depressives N = 6) or bupropion (primary depressives N = 12, secondary depressives N = 6). A differential response to the novel antidepressant bupropion was observed between the two diagnostic subgroups, but no differential response to amitriptyline was observed; patients with primary depression and secondary depression responded equally well to amitriptyline but not to bupropion. Our results provide pharmacological evidence supporting the usefulness of this subclassification of depression.

Adolescent↗
PubMed1977

A comparison of maprotiline (Ludiomil) and amitriptyline (2).

Seventy-five patients were admitted to a double-blind multicentre trial of maprotiline (Ludiomil) and amitriptyline in the management of depression in general practice. Forty-seven patients, twenty-one on maprotiline and twenty-six on amitriptyline completed the study. Statistical analysis of admission data showed that the groups were not strictly comparable in that the maprotiline group contained many more males and had a greater average age. Nevertheless, although there was a suggestion that amitriptyline was faster-acting in the younger age group that received it, there were no statistically significant differences between the two treatment groups as regards onset of effect, clinical efficacy or tolerability.

Adult↗
PubMed1978

Effects of amitriptyline and mianserin on psychomotor skills and memory in man.

1. Twenty volunteers were treated with amitriptyline 25 mg, mianserin 10 mg, and placebo, three times daily for 2 weeks each, in a double-blind cross-over study. Tests of psychomotor function and of learning and memory, were carried out after consumption of alcohol or a placebo drink at intervals during each treatment period. 2. Coordinative and reactive skills were affected by mianserin on the first day only, but by amitriptyline up to day 7 in most of the tests. Both drugs seemed to interact additively with alcohol. 3. Amitriptyline impaired short-term memory span and acquisition, and alcohol enhanced these effects. Mianserin did not affect learning and memory, and did not interact with alcohol in this respect. 4. The differing effects of amitripyline and mianserin are considered in relation to anticholinergic properties.

Adult↗
PubMed1986

A trial of amitriptyline and fluphenazine in the treatment of painful diabetic neuropathy.

We conducted a double-blind, placebo-controlled, crossover study of the effectiveness of amitriptyline and fluphenazine in alleviating the pain of diabetic peripheral neuropathy in six diabetic patients. Pain was evaluated by the patients with a graphic rating scale. A placebo response was found, but no additional effect of amitriptyline and fluphenazine was seen. Although the statistical power of this study was low, these data, when combined with a reevaluation of previous trials of amitriptyline and fluphenazine in the treatment of painful diabetic neuropathy, indicate that there is no justification for the use of these agents in the treatment of painful neuropathy outside of large, controlled clinical trials. Depression as a possible cause of this condition should not go unnoted or untreated.

Adult↗
PubMed1986

Comparative effects of limbitrol and amitriptyline on sleep efficiency and architecture.

Chlordiazepoxide-amitriptyline (Limbitrol) has been shown to be more rapidly effective than amitriptyline alone for treating depression. A double-blind, randomized study was designed to compare the effects of Limbitrol and amitriptyline on insomnia, anxiety, and depression. The rate of improvement of symptoms was faster with Limbitrol. No differences were noted between groups in the degree or rate of improvement of the sleep laboratory parameters nor in sleep Stages 1 to 4. Percentages of rapid eye movement (REM) sleep and REM latency were similarly affected by the drugs, but REM density showed a significantly greater decrease with Limbitrol. Phasic REM factors may be crucial in the role of REM sleep and depression.

Adult↗
PubMed1986

A comparison of the effects of trazodone and amitriptyline on skills performance by geriatric subjects.

Fifteen healthy adults, aged 60 years and older, participated in a double-blind, crossover study of trazodone in comparison with amitriptyline and placebo. A battery of laboratory tests was used to measure drug effects on information processing, attention, and visual-motor skills. Amitriptyline 50 mg impaired vigilance and tracking performance and increased drowsiness. Trazodone 100 mg impaired only the most difficult tracking task. This study demonstrates that cognition and performance are less adversely affected in geriatric subjects by trazodone than by amitriptyline beginning 90 minutes after a single-dosage trial.

Administration, Oral↗
PubMed1985

A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder.

The efficacy and safety of fluoxetine, a new antidepressant agent, were assessed in a double-blind, parallel, randomized study of 44 outpatients with major depressive disorder. Following a 1-week placebo period, patients were randomly assigned to either fluoxetine or amitriptyline for a period of 5 weeks. The mean maintenance dosages were 55 mg/day for fluoxetine and 159 mg/day for amitriptyline. Both drugs were effective in relieving the symptoms of depression. The most frequently reported side effects were nausea and nervousness for fluoxetine, and dry mouth, dizziness, and drowsiness for amitriptyline.

Adult↗
PubMed1985

Amitriptyline for agitation in head injury.

Agitated behavior is frequently associated with traumatic closed head injury. Proactive behavioral intervention is often not successful, and psychopharmacologic agents may result in increasing the targeted behavior through sedation. We describe a 32-year-old woman who developed severe agitation after frontal lobe closed head injury. After failing conservative behavioral management, a therapeutic trial of amitriptyline was initiated. Within two weeks, aggressive outbursts nearly ceased and attention span improved. Serial neuropsychologic assessment before and during amitriptyline therapy documented preservation of cognitive indices along with improvement in Trailmaking tasks. This case suggests that a trial of amitriptyline or other tricyclic antidepressant may be helpful in diminishing agitation associated with frontal lobe damage without impeding cognitive recovery.

Adult↗
PubMed1984

Comparison of the electrocardiographic effect of dothiepin and amitriptyline.

Electrocardiograms of 65 patients treated with dothiepin, a sulphur substituted tricyclic antidepressant, were compared to those of 57 patients receiving amitriptyline and 62 patients given placebo. Amitriptyline produced an average heart rate increase of 10 beats/minute as compared to 5 beats/minute for dothiepin (p less than .02). Amitriptyline also produced a significant prolongation of the corrected QT interval as compared to both dothiepin and placebo (p less than .01 and p less than .001, respectively). Dothiepin had no significant effect on any index of myocardial conduction (PR interval, corrected QT interval, and QRS duration) as compared to placebo.

Adult↗
PubMed1982

A comparative, multicenter trial between bromocriptine and amitriptyline in the treatment of endogenous depression.

A double-blind, multicenter trial compared bromocriptine (Parlodel) with amitriptyline in 83 endogenously depressed patients. The patient sample consisted mainly of agitated endogenous depression, and most of the patients were treated within a daily dose range of 30--50 mg bromocriptine or 120--200 mg amitriptyline. In both the global assessment and the Hamilton Depression Rating Scale, amitriptyline scored higher than bromocriptine, but the differences were not statistically significant. There was little difference between the drugs with respect to tolerability. Bromocriptine's potential role in psychiatry will probably be in those patients in whom an alternative treatment to standard antidepressant therapy is required and a less sedative effect with minimal anticholinergic response is indicated. Bromocriptine's use in Parkinson's disease, where the incidence of depression has been reported to be as high as 37%, has been well documented. Bromocriptine's antidepressant properties add to its therapeutic value in this disease.

Adult↗
PubMed1982

Amitriptyline stimulates weight gain in hemodialysis patients.

Sixteen chronic hemodialysis patients were enrolled in a double blind 13 week study of amitriptyline vs. placebo in non-crossover design. Patients receiving active drug reached therapeutic serum concentrations at doses of 50 to 200 mg/day, but antidepressant effect was not demonstrable. Patients receiving active drug had slightly greater fluctuation in weight pre- vs. Post-dialysis and had slightly greater postural hypotension post-dialysis than control patients. The trend in post-dialysis weight indicated gain in the active drug group and loss in the placebo group; this difference was highly statistically significant. Weight gain in depression and anorexia nervosa patients treated with amitriptyline is reviewed and it is suggested that amitriptyline may be a useful agent in stimulating appetite in other diseases also.

Adult↗
PubMed1976

Dibenzepin and amitriptyline in depressive states: comparative double-blind trial.

Dibenzepin and amitriptyline appeared to be equally efficacious in controlling target symptoms of depressive reactions. These results appear to be consistent with pharmacological profiles of the two drugs which are both tricylic compounds. Control of target symptoms occurred in an undulating and non-progressive manner in both groups. Aggravation of depressive symptomatology in the third week of treatment was noted in both groups and appeared to be clinically very important in the management of depressed patients. Dibenzepin caused relatively fewer side effects which appears to be an advantage over amitriptyline. Dibenzepin appeared to be a suitable alternative for amitriptyline intolerant patients, with moderately severe depression associated with anxiety, especially patients who demonstrated emotional sensitivity or passive dependent personality, and psychosomatic symptoms.

Adult↗
PubMed1980

Plasma concentrations of amitriptyline during single nightly and thrice daily administration. Cross-over study.

Plasma amitriptyline and nortriptyline concentrations were measured in ten depressed in-patients after administration of amitriptyline hydrochloride 75 mg in three divided doses or as a single nightly dose. Mean steady state plasma concentrations during the two dosage regimens were similar. Plasma level differences between dosage schedules at sampling times were small and not significant. It was concluded that the single nightly administration of amitriptyline is a helpful therapeutic schedule which can be used instead of the divided dose when the opportunity is given.

Amitriptyline↗
PubMed1995

Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression.

Paroxetine (30 mg), a selective serotonin (5-HT) reuptake inhibitor, was compared in a double-blind trial to amitriptyline (150 mg) in a sample of 40 inpatients aged 18-65 years who fulfilled Research Diagnostic Criteria for major depression. Patients were studied after a placebo drug washout period of 10 days and after an active 4-week treatment period. Sleep EEG recordings were performed before and at the end of the study as well as during acute treatment (first 2 days) and following withdrawal of active medication. Paroxetine shows an antidepressant effect similar to amitriptyline with a different side-effect profile typical of 5-HT reuptake inhibition. Paroxetine and amitriptyline decreased the amount of REM sleep, a well-known effect of classical antidepressants. Paroxetine also shared with other 5-HT reuptake inhibitors an alerting effect on sleep that was not shown to be detrimental on subjective sleep quality.

Adolescent↗